BOSTON SCIENTIFIC CORPORATION | 7,013 Euro | +0,147 +2,14 % | |
| WKN: 884113 ISIN: US1011371077 Ticker-Symbol: BSX | Frankfurt | 24.05.13 | 08:38 Uhr |
Branche GesundheitswesenAktienmarkt S&P 500 |
|
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 17:02 | Boston Scientific To Participate In The 38th Annual Deutsche Bank 2013 Healthcare Conference | 36 | PR Newswire | |
| NATICK, Mass., May 24, 2013 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38th Annual Deutsche Bank 2013 Healthcare Conference on May 30 in Boston.
Mike... Mehr lesen zu: Boston Scientific To Participate In The 38th Annual Deutsche Bank 2013 Healthcare Conference | ||||
| 23.05. | Vertriebsverbot: OrbusNeich verbannt mit Arnold Ruess und König Szynka Stents von Boston Scientific | 6 | JUVE | |
| 22.05. | New Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix' Renal Denervation System | 51 | PR Newswire | |
| - Interim Data from REDUCE-HTN Clinical Program Presented Today at EuroPCR
PARIS, May 22, 2013 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) today reported interim data from the... Mehr lesen zu: New Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix' Renal Denervation System | ||||
| 22.05. | Boston Scientific: Lotus Valve System Met Primary Endpoint In REPRISE II Trial | 72 | AFX News | |
| WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) announced positive
results from a pre-specified analysis of the first 60 patients enrolled in the
REPRISE II trial evaluating the performance... Mehr lesen zu: Boston Scientific: Lotus Valve System Met Primary Endpoint In REPRISE II Trial | ||||
| 22.05. | Boston Scientific's Lotus Aortic Valve Shows Promise in Study | - | Bloomberg | |
| 22.05. | Boston Scientific Reports Lotus' Valve System Met Primary Performance Endpoint in REPRISE II Trial | 27 | PR Newswire | |
| - New Data Presented In Late-Breaking Clinical Trial Session At EuroPCR Demonstrated Successful Deployment Of The Lotus' Valve In The First 60 Patients With Minimal Paravalvular Regurgitation At 30... Mehr lesen zu: Boston Scientific Reports Lotus' Valve System Met Primary Performance Endpoint in REPRISE II Trial | ||||
| 22.05. | Boston Scientific Reports Results From Trials Evaluating Stent Technologies | 58 | AFX News | |
| WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX) reported positive
results from two trials evaluating new, drug-eluting stent technologies, which
are emerging treatment options for coronary... Mehr lesen zu: Boston Scientific Reports Results From Trials Evaluating Stent Technologies | ||||
| 22.05. | Boston Scientific Announces Results from Promus Premier, Synergy Drug-Eluting Stent | - | Benzinga.com | |
| 22.05. | Boston Scientific (BSX) Reports Positive Results from NG PROMUS, EVOLVE | - | StreetInsider.com | |
| 22.05. | Boston Scientific Promus PREMIER' And SYNERGY' Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy Data | 35 | PR Newswire | |
| PARIS, May 22, 2013 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies... Mehr lesen zu: Boston Scientific Promus PREMIER' And SYNERGY' Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy Data | ||||
| 21.05. | Boston Scientific competitor calls the cops to seize 'illegal' stents in Germany | 5 | bizjournals | |
| 21.05. | Boston Scientific Long Term Data Demonstrate Bronchial Thermoplasty Treatment Benefits Persist Out to Five Years in Patients with Severe Asthma | 28 | PR Newswire | |
|
NATICK, Mass., May 21, 2013 /PRNewswire/ -- Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE:... Mehr lesen zu: Boston Scientific Long Term Data Demonstrate Bronchial Thermoplasty Treatment Benefits Persist Out to Five Years in Patients with Severe Asthma | ||||
| 21.05. | OrbusNeich Seizes 190 Boston Scientific Stents in Germany in Patent Infringement Suit | 6 | Benzinga.com | |
| 21.05. | OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings | 64 | PR Newswire | |
| WIESBADEN, Germany, May 21, 2013 /PRNewswire/ --Medical device manufacturer OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively "OrbusNeich") today announced that it... Mehr lesen zu: OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings | ||||
| 20.05. | Medtronic patent dispute with Boston Scientific goes to Supreme Court | 4 | bizjournals | |
| 17.05. | Boston Scientific begins platinum stent trial | 6 | Platinum today | |
| 17.05. | Boston Scientific Presents Clinical Data at Digestive Disease Week | 42 | PR Newswire | |
| NATICK, Mass., May 17, 2013 /PRNewswire/ --Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in Digestive Disease Week (DDW®) 2013, May 18-21 in Orlando, Fla. More than 24 clinical... Mehr lesen zu: Boston Scientific Presents Clinical Data at Digestive Disease Week | ||||
| 17.05. | Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 | 66 | PR Newswire | |
| NATICK, Mass., May 17, 2013 /PRNewswire/ --Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris.
"We are pleased to present... Mehr lesen zu: Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 | ||||
| 16.05. | Vascular Solutions Issues Patent Infringement Complaint Against Boston Scientific | 3 | Benzinga.com | |
| 16.05. | Vascular Solutions Files Patent Infringement Complaint Against Boston Scientific | 1 | Benzinga.com | |
